Kyverna Therapeutics (KYTX) Net Cash Flow (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Net Cash Flow of -$91.9 million for Q1 2026, down 202.18% on a QoQ basis from $89.9 million in Q4 2025, and down 131.27% year-over-year from $293.9 million in Q1 2025.
Kyverna Therapeutics (KYTX) Net Cash Flow (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at -$91.9 million for Q1 2026.
- Quarterly Net Cash Flow fell 131.27% year-over-year to -$91.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.7 million (up 85.26% YoY) and the FY2025 annual result came in at $27.5 million, down 55.64% from the prior year.
- Net Cash Flow was -$91.9 million for Q1 2026 at Kyverna Therapeutics, down from $89.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $189.6 million in Q1 2024 and bottomed at -$92.7 million in Q2 2024.
- A 4-year average of -$425538.5 and a median of -$8.1 million in 2024 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 9137.46% in 2024, while the deepest fall reached 779.06% in 2024.
- Kyverna Therapeutics' Net Cash Flow stood at $11.7 million in 2023, then slumped by 168.93% to -$8.1 million in 2024, then jumped by 1216.72% to $89.9 million in 2025, then slumped by 202.18% to -$91.9 million in 2026.
- Business Quant data shows KYTX's Net Cash Flow at -$91.9 million in Q1 2026, $89.9 million in Q4 2025, and -$19.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -91.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.90 Mn |
| Mar 31, 2026 | -91.90 Mn |
| Dec 31, 2025 | 89.94 Mn |
| Dec 31, 2025 | 89.94 Mn |
| Sep 30, 2025 | -19.28 Mn |
| Sep 30, 2025 | -19.28 Mn |
| Jun 30, 2025 | -3.45 Mn |
| Jun 30, 2025 | -3.45 Mn |
| Mar 31, 2025 | -39.74 Mn |
| Mar 31, 2025 | -39.74 Mn |
| Dec 31, 2024 | -8.05 Mn |
| Dec 31, 2024 | -8.05 Mn |
| Sep 30, 2024 | -26.97 Mn |
| Sep 30, 2024 | -26.97 Mn |
| Jun 30, 2024 | -92.67 Mn |
| Jun 30, 2024 | -92.67 Mn |
| Mar 31, 2024 | 189.65 Mn |
| Mar 31, 2024 | 189.65 Mn |
| Dec 31, 2023 | 11.68 Mn |
| Dec 31, 2023 | 11.68 Mn |